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Abstract 
 
Crohn’s disease is a chronic relapsing and remitting inflammatory disorder of the 
gastrointestinal tract, associated with significantly morbidity due to both symptoms and 
complications that have a considerable detrimental impact on a patient’s quality of life. An 
early treat to target approach with disease modifying agents has been shown to significantly 
improve long term outcomes, demonstrated by a number of therapeutic targets in a number of 
modalities. This review will outline the current treatment targets and measures of disease 
burden in Crohn’s disease.   
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Introduction 
 
Crohn’s disease (CD) is a chronic relapsing and remitting inflammatory disorder of the 
gastrointestinal (GI) tract with a prevalence of up to 200 per 100,000 (1, 2). The majority of 
patients require long term medical therapy and almost half of patients will require surgery at 
10 years (3). This can have a significant impact on a patient’s quality of life (4).  
 
The traditional management of CD involves a stepwise escalation of treatment but this 
approach can lead to a delay in those at high risk of disease progression. The correlation 
between symptoms and endoscopic disease activity is poor so there is a risk of under 
treatment. 
 
Advances in the treatment of Rheumatoid Arthritis (RA) has led the way to the evolution of 
treatment targets in CD. The introduction of disease modifying agents, especially anti-tumour 
necrosis factor (anti-TNFs), in addition to earlier treatment has led to reduction in joint 
destruction and associated morbidity traditionally associated with RA. This treatment strategy 
has led to the ‘treat to target’ approach, which involves regular assessment and treatment 
adjustment using validated outcomes measures.  
 
4 
 
In CD intervening at an early stage could also potentially alter disease outcomes but 
definitions of treatment targets are not well defined (5). A future ‘treat to target’ approach 
would aim to halt the biological progression using histological healing, clinical and surrogate 
markers of disease activity. Current recommendations are based on the 2015 Selecting 
Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) programme which was 
developed to determine twelve possible ‘treat to target’ goals. One such target was the 
resolution of abdominal pain and change in bowel habit. However, symptom resolution was 
not sufficient to be recommended as a target and objective evidence of inflammation is 
required when considering treatment alterations. Another target was the absence of ulceration 
with objective endoscopic evidence demonstrating this. Histological remission was not 
recommended as a treatment target. In addition, inflammation resolution on cross sectional 
imaging was suggested as an alternative to endoscopy. The patient reported outcomes (PRO) 
recommended were the resolution of abdominal pain and the normalization of bowel 
movements. The reassessment interval for PROs was recommended every three months until 
resolution and six to twelve months thereafter. The use of laboratory markers C-reactive 
protein (CRP) and faecal calprotectin (FCP) were deemed useful as adjunctive measures to 
prompt further investigations but not as targets themselves. This programme was the first to 
suggest composite end-points, including both clinical and endoscopic remission with 
assessment intervals for these targets (6).   
 
Further prospective work in this area will enable guided, personalized patient therapy with 
the potential use of tools such as serum drug levels and antibody levels to enable positive 
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treatment modifications to be made (5, 6). This chapter will examine the current evolution of 
treatment targets and measures of disease burden in CD.  
 
 
 
Evolution of treatment targets and measures of disease burden 
Primary treatment targets 
Clinical Remission-Clinician Reported Activity Indices 
Crohn’s disease activity index (CDAI) 
Treatment targets are well defined in a number of chronic diseases but there are discrepancies 
between endoscopic and symptom based disease activity in CD (7).  Clinical remission, 
therefore, requires a combination of both symptomatic and inflammatory resolution. The 
Crohn’s disease activity index (CDAI) was developed in the 1970’s and has been used in a 
variety of clinical studies to try and provide an accurate, objective and reproducible clinical 
assessment. Eight variables were selected that correlated with the physician global 
assessment of CD. The variables used in this equation included: number of stool frequency, 
abdominal pain, subjective measure of general well-being, presence of complications, use of 
agents to counteract diarrhoea, abdominal mass, haematocrit and body weight. Scores ranged 
between 0 and 600: a score <150 is associated with remission, >150 indicative of active 
disease and >450 signifying severe disease (8, 9).  Clinical response using CDAI was defined 
as a drop in 70 points over two patient visits or a drop of 100 points from baseline (10). This 
score, as others, is prone to inter observer variability but this can be minimised by clear 
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instructions (11). Other problems with this score relate to its complex structure, subjectivity, 
not always been reproducible and cofounders associated with other GI diseases. The score is 
also heavily weighted by stool frequency, thus does not adequately reflect disease activity in 
proximal locations where stool frequency is not a prime symptom (12, 13). However, CDAI 
still remains very commonly utilised for assessing disease activity in CD clinical trials 
despite correlating poorly with laboratory, endoscopic and histological markers (10, 14-16). 
CDAI has been modified over the years with the short CDAI (sCDAI) correlating with the 
original index (17). The disease severity can now be further classified as mild active (CDAI 
150-220) and moderate-severe (CDAI 220-450) (14). It is now used as an index clinical 
response and remission in addition to disease severity.  
 
The Harvey Bradshaw Index 
The Harvey Bradshaw Index (HBI) is a much simpler disease activity score used in CD and 
correlates with CDAI (18). This score is more suited for routine clinical practice and requires 
less data for calculation. It comprises of general well-being, abdominal pain, stool frequency, 
abdominal mass and complications. A score of 5 to 7 is considered mild, 8 to 15 moderate 
and >16 severe disease. Clinical remission is considered if score is ≤4 points and clinical 
response if there is ≥3-point drop. (19).  
 
Patient Reported Outcomes (PRO) 
PROs aim to improve the capture of patient’s symptoms as objective markers fail to capture 
this. Also clinician reported activity indices do not always correlate with objective measures 
7 
 
of inflammation, therefore, scores which examine bowel, systemic, emotional and social 
function have been developed (20). The Food and Drug Administration recommended the 
development of co-primary endpoints in clinical trials to incorporate objective measures of 
inflammation with PROs. This is to help achieve more patient-centred management.  
 
CD specific PRO (CD-PRO) is currently under development for use in clinical trials, 
concentrating on bowel signs, symptoms, quality of life, emotional elements and coping 
behaviours. Other measures include CD PRO-2 (which consists of the components of 
abdominal pain and stool frequency) and CD PRO-3 (consisting of abdominal pain, stool 
frequency and general well-being) (21). Both performed well when compared to CDAI. Trial 
data from methotrexate in CD using regression analysis showed that CDAI scores of 150, 220 
and 450 correspond with a CD PRO-2 and CD PRO-3 score of 8, 14, 34 and 13, 22, 53 
respectively (22). This outcome measure should be patient-centred and assessed on a regular 
basis (three monthly) until symptom resolution occurs and then six to twelve monthly 
afterwards (6).  In addition, patient based HBI (P-HBI) has also been compared with 
physician based HBI and also showed a good correlation (23).  
 
The main PRO in CD, as in Ulcerative colitis (UC), is the improvement in quality of life 
(QoL) (24). The Patient Reported Outcomes Measurement Information System (GI-
PROMIS) symptom scale was developed for evaluating physical, mental and social health 
(25). GI-PROMIS was recently evaluated on 2,378 CD and 1,455 UC respondents and was 
shown to be strongly associated with disease activity and QoL indices (26).  
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PROs have the potential to act as a therapeutic target in future IBD trials, when combined 
with clinical features (e.g. absence of abdominal pain/diarrhoea) and resolution of 
inflammation (on endoscopy/cross sectional imaging) (6) with the ultimate hope to improve 
patient-centered outcomes.  
 
 Endoscopic Remission 
Distinctive findings of CD include oedema, erythema, nodular mucosa and ulcerations. 
Friability, spontaneous bleeding in addition to ulceration depth and size correlates with 
disease severity (27). The absence of ulceration is the most significant endoscopic target in 
CD. Where endoscopy is not appropriate or the disease is not within reach of an 
ileocolonoscopy, cross-sectional imaging is an alternative. Endoscopic scoring (in addition to 
other objective markers like faecal calprotectin) correlates better with inflammation than 
CDAI (7, 28). Mucosal healing is associated with reduced corticosteroid use, reduced 
surgical rates in addition to improved clinical response and lower relapse rates (29). 
 
CD Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score for CD (SES-
CD) are validated measures of endoscopic disease activity. CDEIS evaluates four parameters 
describing the type of ulceration and surface involved in five areas of the lower intestinal 
tract: the rectum, left and sigmoid colon, transverse colon, right colon and ileum (30). CDEIS 
<3 correlates with remission, ≥3 active disease and a drop in the total score by >5 points 
signifies clinical response (31, 32). SES-CD is more simplified and assesses the size, surface 
of ulcers, the extension of disease involvement and stenosis. SES-CD <2 correlates with 
remission, ≥3 active disease (33, 34).  
9 
 
 
Rutgeerts score, developed nearly 30 years ago, can be used to monitor post-operative 
recurrence at the ileo-colonic anastomosis level. This score is used to evaluate recurrence 6 to 
12 months after surgery.  Endoscopic examination can detect up to 70% of recurrent disease 
six to twelve months after. The score consists of five categories (i0, i1, i2, i3 and i4) for 
describing endoscopic findings at the anastomosis and neo-terminal ileum. Lesions examined 
for include aphthous ulcers, inflamed mucosa, ulcers, nodular mucosa and stenosis. Low 
scores (i0, i1) correlate with recurrence rates of 6% in five years. In higher scores (i3, i4) 
recurrence was up to 100%. Scores above i2 are considered as disease recurrence. This scores 
is widely used in clinical practice despite the lack of validation studies (35, 36).  
 
Schnitzler et al investigated mucosal healing rates and the need for surgery. They 
demonstrated that mucosal healing was associated with a fifty-percentage reduction in 
surgery rates during the follow up period. After the follow up period, 42.2% of patients with 
mucosal healing required hospitalization when compared to 59.3% without mucosal healing 
(p=0.0018) (37). Subjects with endoscopic remission are associated with significantly higher 
corticosteroid-free remission rates when compared with those without (70.8% vs 27.3% 
p=0.036) (38). Allez et al described the probability of surgery with severe endoscopy features 
at 1, 3 and 8 years as 31%, 42% and 62% respectively (39). Mucosal healing leads to better 
long-term remission rates and improved quality of life (40-42). Endoscopic post-operative 
recurrence within 12 months of resection is a good predictor of clinical recurrence (35). 
Mucosal healing is also associated with reduced colorectal cancer in UC but no data is 
available for CD (43).  
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A prospective cohort study using 740 Norwegian patients (both UC and CD) described 
improved clinical outcomes with mucosal healing on long-term follow up. Patients were 
assessed at year 1 and 5. Those in endoscopic remission by year 1 had significantly lower 
resection rates (11% vs 20%) at 5 years. Mucosal healing was associated with reduced 
inflammation at 5 years (p=0.02) and reduced corticosteroid use (p=0.02). Endoscopic 
mucosal healing is a major therapeutic target in CD, associated with both clinical and 
corticosteroid-free remission, reduced hospitalisation and surgery (29, 44).  
 
However, symptoms and mucosal healing do not always correlate in CD. Deep remission is 
the term used when clinical remission is also associated with mucosal healing. It is not 
completely clear as to whether achieving deep remission is an effective way to monitor 
disease progression or whether this target always needs to be achieved before stepping down 
treatment (45). Few studies have examined mucosal healing in CD as a therapeutic endpoint. 
Two such studies investigating mucosal healing induction with infliximab and adalimumab, 
showed that the pooled rate of healing when compared with placebo were 29% and 7% 
respectively. Anti-TNFs were more effective in inducing mucosal healing with an odd ratio 
3.93 (95% CI 0.77 – 20.10) (41, 46) when compared to placebo. The SONIC trial reported 
mucosal healing rates for azathioprine, infliximab and combination therapy of infliximab and 
azathioprine) of 17%, 30%, and 44% respectively. Combination therapy showed statistically 
significant higher mucosal healing rates than azathioprine or infliximab alone (47). These 
results were similar Lemann et al report comparing azathioprine with combination therapy 
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(48, 49). It is important to note that corticosteroids, do not achieve mucosal healing (50, 51) 
and hence do not positively affect long term outcomes.  
 
In addition, risk of clinical relapse is reduced when endoscopic remission is achieved (52). 
Thus, mucosal healing is a very important endpoint in routine clinical practice and in clinical 
trials. However, there are some important limitations with mucosal healing. Firstly, the time 
period required for endoscopic follow up is not completely clear. Secondly, mucosal healing 
is dependent on endoscopist interpretation and subject to observer variability. Thirdly, 
endoscopic assessment is costly and can be associated with significant risks. In addition, it 
remains unclear what degree of mucosal healing is required to alter disease course (53). 
Finally, mucosal healing and clinical features do not always correlate which has led to the 
requirement of a combination of endpoints to monitor disease activity (54).  
 
Cross sectional Imaging 
Cross sectional imaging (magnetic resonance imaging (MRI), computer tomography (CT) 
and ultrasound (US) are underutilised tools in CD activity assessment. At present imaging is 
useful to assess areas not easily accessible by colonoscopy.  
 
Although endoscopy remains the gold standard for assessing the mucosa in CD, magnetic 
resonance enterography (MRE) shows good correlation with the presence and severity of 
mucosal lesions. MRE measurements are based on bowel wall thickening, enhancement of 
the bowel wall after administration of intravenous contrast with gadolinium, presence of 
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ulcers, mural oedema, regional enlarged lymph nodes (>10 mm), peri-enteric vascularization, 
peri-enteric fluid, fat stranding, and fibro-fatty proliferation. At present, it is unclear whether 
changes assessed by MRI are adequate to measure response to biologic therapy in 
comparison to endoscopy and clinical scores. Ordás et al measured the accuracy of MRE in 
measuring response to therapy. The accuracy of MRE to determine ulcer healing and 
endoscopic remission was 90% and 83% respectively. There was also good correlation of 
CDEIS with the magnetic resonance index of activity (MaRIA score) which grades wall 
thickness, oedema, contrast enhancements and ulceration (r = 0.51; p < 0.001).  
MRE is minimally invasive, but further studies are needed to study the response during 
therapy (55).  
 
MRI characteristics have shown fair to good interobserver variability (kappa = 0.62 to 0.66) 
across all observers in other studies. The interobserver variability for length of disease, 
pattern of enhancement, oedema and wall thickness has been shown to be 0.62, 0.62, 0.66 
and 0.69 respectively (56). Measuring bowel peristaltic motion with MRI also enables 
quantification of bowel function (57). Bowel motility is reduced during active disease, with 
extent of reduction correlating with the severity of inflammation (58). Also MRI motility has 
been shown to improve with anti-TNF treatment (median=73.4% increase from baseline vs 
non-responders median=25% reduction, p<0.001), thus MRI motility has the potential to 
predict long-term response to biologic therapy (59).  
 
With regards to other imaging modalities, a retrospective CT enterography study revealed 
that 60% patients had a radiological response to infliximab. Due to the nature of this study it 
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is difficult to obtain the true accuracy of this modality (60). US is an easily available, non-
invasive tool and has a sensitivity and specificity for disease activity of 0.84 and 0.98 
respectively. A disadvantage of this technique is a lower accuracy for disease proximal to the 
terminal ileum and that it is examiner dependent (61).  US findings associated with CD 
include a bowel wall thickness greater than 4 mm, reduced compressibility, stenosed lumen 
and presence of fistulas or abscesses. US is useful as a first approach tool but needs 
confirmation by other modalities (62).  
 
The ‘Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound 
for the extent and activity of newly diagnosed and relapsed Crohn's disease’ (METRIC) 
multicentre trial assessed the diagnostic accuracy of MRE and small bowel US for the extent 
and activity of disease in individuals with CD. The primary outcome was the difference in per 
patient small bowel sensitivity. A total of 284 patients completed the study. Sensitivity for 
extent and presence for MRE was 80% (95% CI 72–86) and 97% (95% CI 91–99) 
respectively.  The sensitivity for US for disease extent and presence was 70% (95% CI 62-78) 
and 92% (95% CI 84-96) respectively. The difference between MRE and US was significant: 
extent 10% (95% CI 1–18, p=0·027) and presence 5% (1–9, p=0·025). The specificity for 
MRE for disease extent and presence was 95% (95% CI 85-98) and 96% (95% CI 86-99) 
respectively. Using US, the specificity for extent and presence was 81% (95% CI 64-91) and 
84% (95% CI 65-94). There was a significant difference between MRE and US for extent and 
presence of 14% (1–27, p=0·039) and 12% (0–25, p=0·054). Both modalities were accurate 
at detecting disease but MRE performed significantly better (63). 
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Horsthuis et al compared the accuracy of US, MRI and CT in diagnosing IBD in a meta-
analysis but found no significant different in each modality with sensitivity ranging from 
84% to 93% and specificity from 93% to 96%. CT involved radiation exposure and was less 
accurate when compared to MRI (64). All modalities are sensitive for the detection of 
abscesses but detection is dependent on the anatomical location.  
 
Cross sectional imaging has an advantage over endoscopy in its ability to assess the entire 
luminal wall, to examine the small bowel and diagnose penetrating complications. In research 
settings, MRI screening examinations would allow for the selection of patients with active 
disease without complicated penetrating disease that are more likely to respond to therapy. 
Cross sectional imaging is also unable to detect mild disease. At present, there is only weak 
correlations with cross sectional imaging and clinical activity indices and biomarkers (62). 
 
Histology 
Ongoing inflammation in CD leads to a significantly increased risk of relapse, surgery and 
the development of colorectal cancer (38, 65). Scoring systems are limited in CD due to the 
transmural or discontinuous nature of disease and the absence of a standard definition of 
histological remission. Baars et al investigated the prognostic value of histological 
inflammation and found it was not associated with adverse outcomes such as relapse rates 
and surgery as a large proportion of patients in clinical remission had histological evidence of 
inflammation. The inconsistent and patchy distribution of inflammation did make 
interpretation difficult (66), with other studies also showing microscopic inflammation in 
quiescent disease (67, 68). Few trials to date have used histological remission as a therapeutic 
15 
 
end-point in CD.  D'Haens et al investigated response to infliximab and showed an 
improvement in inflammatory infiltrate but architectural changes remained after 28 days of 
infliximab treatment (69). Due to the present lack of convincing data histological remission 
should not be treatment target in CD (6) 
 
Treat-to-target studies 
 
The ‘treat to target’ approach is based on international IBD expert consensus and describes a 
variety of targets. These included: patient reported outcomes, remission using endoscopic 
standards and the laboratory markers CRP and FCP. The use of cross-sectional imaging was 
suggested as an alternative to endoscopy and composite end-points. A number of treat to 
target studies have been completed. Colombel et al recently conducted a multi-centre, 
randomised controlled open label trial entitled ‘Effect of tight control management on 
Crohn’s disease (CALM study).’ They compared endoscopic and clinical outcomes of 
patients with active CD. Patients with endoscopic evidence of active disease, CDEIS >6 and 
CDAI 150–450, who were naïve to immunomodulators or biologics were recruited. Patients 
were randomised to a tight control algorithm using biomarkers and clinical symptoms or a 
clinical management algorithm using solely clinical symptoms in a 1:1 depending on 
smoking status, disease duration and weight after an 8-week induction period with 
prednisolone therapy. Treatment was intensified in a controlled manor for both groups. The 
options were either no treatment, induction with adalimumab then two weekly, weekly or 
weekly with the addition of daily azathioprine. Treatment failure criteria for the tight control 
group was defined as: faecal calprotectin (FCP) ≥250 μg/g, C-reactive protein (CRP) 
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≥5mg/L, CDAI ≥150, or prednisone use. In the clinical management group this was 
considered as a CDAI decrease of <70 points compared with baseline or CDAI >200. Patients 
were reviewed every 12 weeks for 24 months and treatment was escalated if clinical 
remission was not achieved. The primary endpoint was mucosal healing (CDEIS <4) without 
ulceration at 48 weeks. The investigators compared endoscopic and clinical outcomes in 
moderate to severe CD. 244 patients were recruited and there was a significant difference in 
achieving the primary outcome in the tight control group when compared to the clinical 
management group 46% vs 30% adjusted risk difference of 16·1% (95% CI 3·9–28·3; 
p=0·010). Better clinical and endoscopic outcomes occurred in participants exposed to 
controlled escalation guided by clinical and biomarker parameters in early CD patients. This 
study was the first treat to target study measuring objective markers of inflammation (70). 
Decision-making based on objective biochemical markers of disease activity is effective in 
CD management (70) and enhances mucosal healing rates. 
The ‘Randomized evaluation of an algorithm for Crohn’s Disease treatment’ (REACT) study 
compared the effectiveness of the conventional ‘step up’ treatment with early combined 
immunosuppressive (ECI) ‘accelerated step up’ treatment with adalimumab and an 
immunomodulator (anti-metabolite). This open label cluster randomised controlled trial 
assigned patients 1:1 to either therapy. Over 800 patients were recruited to each arm. The 
primary endpoint was corticosteroid-free remission at 52 weeks (HBI <4). The secondary 
endpoint was adverse events at 24 months.  ECI was not shown to be more effective than 
conventional therapy in symptom control but there was a major reduction in adverse 
outcomes such as surgery rates and hospital admissions with a hazard ratio of 0·73, 95% CI 
0·62 to 0·86, p=0·0003 for the ECL arm (71). The use of corticosteroid-free remission as a 
primary endpoint could explain the negative results in this trial. This study highlighted the 
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limitations of using clinical symptom-based scores. There was no difference between the 
clinical scores but a clear difference in adverse events, therefore, suggesting clinical 
symptoms are not good predictors of important disease outcomes.  
 
‘The enhanced algorithm for Crohn's treatment incorporating early combination therapy’ 
(REACT 2) study is currently underway investigating CD related complications at 6 and 12 
months and the proportion of patients in deep remission without progression of disease. It 
investigates whether the use of enhanced algorithm with ECI and endoscopic assessment 
improves patient management when compared with conventional step wise care. 1200 CD 
patients treated with adalimumab and immunomodulator will be randomized into a symptom-
based treatment (standard care) or endoscopy-based escalation. This study will provide 
evidence to help determine whether the achievement of mucosal healing as a treat to target is 
achievable and whether mucosal healing improves outcomes (72).  
 
Up to 90% CD patients who have undergone surgery, develop recurrence at the anastomosis 
site within 12 months (35, 73). Risk factors associated with recurrence of disease includes 
smoking, perforating disease, previous resection and primary anastomosis (74, 75). ‘The 
post-operative Crohn’s endoscopic recurrence study’ (POCER) conducted by De Cruz et al 
aimed to identify the optimal strategy to prevent post-operative recurrence. This randomised 
controlled trial conducted was in Australia and New Zealand. CD patients who underwent 
intestinal resections received 12 weeks of therapy with metronidazole. High risk patients also 
received a thiopurine or adalimumab depending on individual tolerance. Patients were 
randomised to a colonoscopy at 6 months (active practice) or no colonoscopy (standard 
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practice) in a 2:1 allocation. Patients with endoscopic recurrence (Rutgeerts score ≥i2) at 6 
months received stepped up treatment: thiopurine, two weekly adalimumab with thiopurine or 
weekly adalimumab. The primary outcome was endoscopic recurrence at 18-months. Central 
endoscopic readers were blinded but not patients and clinicians. 177 patients were included. 
Endoscopic recurrence was significantly lower in the active group when compared to the 
standard 49% vs 67% (p=0·03) respectively. Secondary outcomes showed that mucosal was 
more likely to be maintained in active group, 22% vs 8% (p=0·03). Smoking increased the 
risk of endoscopic recurrence (odds ratio 2·4, 95% CI 1·2–4·8, p=0·02). Smoking or having 
two or more of the risk factors associated with recurrence doubles the risk of post-operative 
recurrence. In summary, treatment guided by recurrence risk, early colonoscopy and therapy 
escalation during recurrence was better than conventional therapy alone for reducing 
recurrence post-surgery. Drug therapy was best adjusted according to early recurrence and 
led to improved disease control. Low risk patients still required monitoring (76). Mowat et al 
also conducted a multi-centre trial investigating mercaptopurine verses placebo to prevent or 
delay post-operative recurrence. Mercaptopurine was only effective in preventing post-
operative recurrence in smokers (77).  5-aminosalicylates (5-ASA) do not provide sufficient 
treatment benefit in preventing post-operative recurrence (78).  
 
In addition, a randomised controlled trial of infliximab verses placebo in 297 CD patients 
showed it was also effective in reducing post-operative recurrence. Primary end-points were 
clinical recurrence (CDAI >200 and a 70 increase from baseline, Rutgeerts score  i2 or 
development of penetrating disease prior to 76 weeks). Secondary end-point was endoscopic 
recurrence (Rutgeerts score  i2 or development of penetrating disease). Clinical recurrences 
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were lower in the infliximab group compared to placebo but this was not statistically 
significant, 12.9% vs 20% respectively. The absolute risk reduction with infliximab was 7.1% 
(95% CI 1.3-15.5, p=0.097).  Endoscopic recurrence was lower with infliximab when 
compared to placebo, 30.6% vs 60% respectively. The absolute risk reduction with infliximab 
was 24.9% (95% CI 18.6-40.2, P<0.001). Individuals who were previously treated with anti-
TNF therapy or previous surgery were at greatest risk of recurrence (79).  
 
Finally, a meta-analysis indicated that imidazole antibiotics reduced endoscopic recurrence 
relative risk 0.44; 95% CI 0.26–0.74 and clinical recurrence 0.23; 95% CI 0.09–0.57 when 
compared to placebo (80).  
 
Biomarkers and Clinical Scores 
 
Biomarkers 
Non-invasive biomarkers such as FCP and CRP are effective as decision making tools but 
should not be treatment end-points because of the lack of evidence. Benefits of these 
biomarkers include being non-invasive and cost effective. The most robust data to predict 
clinical and endoscopic response is raised CRP at baseline (10.3mg/L) and normalisation (7, 
81). The ‘Stop infliximab in patients with CD’ (STORI) study retrospectively analysed 115 
CD patients in whom infliximab was withdrawn. They described the long-term outcome of 
patients in remission after the withdrawal of treatment. 20% of patients did not encounter 
complications or re-start biologic therapy 7 years after withdrawal. Independent predictors of 
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complications were shown to be upper-gastrointestinal disease, haemoglobin level and white 
blood cell count. Patients had a 40% risk of major complications when more than two of 
these factors were present following withdrawal (82).  Further studies have shown that a CRP 
>5 mg/L, haemoglobin level ≤145 g/L and a white cell count >6x109/L predicts relapse in 
CD when biological therapy is withdrawn (83, 84). In a sub-analysis CRP levels at baseline 
and 14 weeks were identified as predictors of response to infliximab. High baseline CRP was 
associated with maintained remission, however, there was no optimal cut-off for CRP which 
makes clinical translation into every day practice problematic (83). Similarly, CRP >20 mg/L 
and haemoglobin level <120 g/L have been shown to be good predictors of relapse in 
azathioprine withdrawal (85).  
 
FCP better reflects inflammation at the mucosal level and is associated with endoscopic and 
clinical scoring indices. A change in FCP correlates with endoscopy scores and a high FCP is 
associated with a significant higher one-year risk of relapse in CD. However, in the Gisbert et 
al study the sensitivity was low at 28% and specificity 93% (7, 86-88). FCP is also a useful 
marker in predicting relapses post intestinal surgery (76). Sipponen et al showed that there 
was a drop from 1173 μg/g to 130 μg/g with anti-TNF therapy, with good correlation shown 
between FCP and endoscopy severity scores (Spearman’s rank-order correlation = 0.561) but 
no correlation with histological scores (87). A review of six studies looking at both CD and 
UC found that higher FCP measured in asymptomatic individuals on a minimum of two 
occasions were associated with increased rate relapses by 3 months. Normal values were also 
associated with lower rates of relapses (89). Wright et al investigated whether FCP could 
substitute endoscopy assessment of the mucosa and found that a FCP >100 μg/g was 
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indicative of endoscopic recurrence with a sensitivity, specificity and negative predictive 
value of 89%, 58% and 91% respectively. FCP had a higher accuracy of predicting 
recurrence than CRP and CDAI (90). However, its sensitivity maybe affected by disease 
location but data is limited. A systemic review of the diagnostic accuracy of FCP by disease 
location described the median sensitivity and specificity values for small bowel as 75% 
(range 42.9% - 100%) and 75% (range 50% -100%) respectively. For the large bowel, the 
sensitivity and specificity median values were 94% (range 8.9%-100%) and 71% (range 
28.6%-100%) respectively (91). Ultimately, more data is required before FCP can be 
recommended as a treatment target (6).  
 
Limited evidence to date is insufficient to recommend these non-invasive biomarkers as 
therapeutic targets in CD and they are not yet a safe or effective surrogate for endoscopy, 
clinical and radiological assessments. Their role is to mainly act as an adjunct measure to 
highlight the need for further investigations in CD. Although used in clinical scoring indices, 
there is no evidence for other biomarkers like ESR, serum albumin and haemoglobin being 
effective as a therapeutic goal in CD (92).  
 
Clinical Scores 
The Lémann score was developed to measure cumulative bowel damage and disease burden. 
It measures bowel damage at specific time points, progression over time, identifies high risk 
patients and compares effects of therapy on disease progression. This score combines 
information from clinical, endoscopic and imaging from all segments of the intestinal tract 
into a single score. This score was developed to guide therapy in CD (93). Pariente et al 
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performed a multicentre prospective study assessing the Lémann score in assessing bowel 
damage. The overall correlation coefficients between predicted and investigator evaluations 
was 0.84. Patients with a disease duration of less than two years have less bowel damage than 
individuals with a longer duration of disease (94). High scores at presentation, increased 
disease duration, clinical activity and a history of surgery were associated with bowel damage 
(95). The Lémann score gradually increases within 10 years in a minimum of two-thirds of 
CD patients. Patients with progression of this score are at higher risk of surgery, disease 
relapses and the use of health care services.  Lémann score measurements over time could 
serve as a future marker of disease and prognosis, therefore, acting as a useful therapeutic 
target (96). Limitations of this score are due to its complex interpretation, requiring specialist 
training and its time-consuming nature.  
 
Quality of life 
 
Improved quality of life and prevention of disability are key targets in the management of 
CD. This is assessed by the IBD questionnaire (IBDQ). A low IBDQ score is associated with 
female sex, recurrent admissions for flare of disease, lower education level, surgery and 
disease recurrence (97). A specific work related questionnaire has been validated for 
measuring work related disability in CD (98). Disability refers to both the subjective and 
objective effects on a patient’s life. The IBD disability index (IBD DI) which examines body 
structures and function, activity and the environment was developed in 2012 according to the 
standard WHO process.  The aim of this index was to evaluate the long-term functional 
effects of CD in research settings and will form the basis of a new disease modification 
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endpoint. Prior to this there were no other index to assess disability (99). This index was 
recently validated on both UC and CD patients. The inter-observer and intra-observer 
reliability were 0.91 and 0.54 respectively. There was good correlation with IBDQ. Factors 
associated with higher scores were disease activity (p<0.0001), female sex (p<0.001) and 
duration of disease (p=0.02) (100). Farré et al evaluated the correlation between the Lémann 
score and IBD DI in a large prospective cohort study. Disease duration, activity and anal 
lesion location were associated with bowel damage. Female sex, lesion location and disease 
activity were associated with IBD DI but correlation between the Lémann score and IBD DI 
were poor (101).  
 
Disease burden, early treatment and impact of disease duration 
 
In terms of disease burden, Fiorino et al investigated the effect of anti-TNF treatment on 
bowel damage (disease activity and complications) using the Lémann score on 30 CD 
patients in a prospective single centre cohort study. Patients were followed up for 32.5 
months. Therapy was associated with a significant reduction in Lémann score at 12 months 
(p=0.007). CD patients whose scores progressed were more likely to undergo major 
abdominal surgery (hazard ratio 0.19, p=0.005). Anti-TNF therapy was shown to reverse 
bowel damage, demonstrating that the Lémann score may be able predict major surgery in 
this cohort of patients. This provided some evidence that anti-TNF are potential disease 
modifying treatments that can hinder or reverse the structural bowel damage seen in CD. 
Anti-TNFs have been shown to maintain mucosal healing but whether bowel damage is 
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reversible with this therapy is largely unknown. This is vitally important to determine how 
effective biologics are at reversing bowel damage in this transmural disease (102).   
 
There is currently insufficient long-term follow up data on disease burden in CD, but as seen 
in RA the use of early disease modification agents may lead to the halting of disease 
progression and an improvement in a patient’s quality of life. This is demonstrated by the 
declining rate of surgical resection for CD, with elective surgery becoming more common 
than emergency surgery (103). The advantages of early intervention include a greater rate of 
early disease control in terms of remission rates, adjusting the disease outcome in terms of 
hospital admission, surgery, bowel damage and surgery. The effectiveness of biologics is 
greater if used early and reduces the risk of undertreatment that can be associated with step 
up approaches. Downsides include overtreatment of individuals, lack of quality evidence and 
the fact that current monitoring and risk stratification is not currently adequate for this 
approach (104). The ‘Personalised medicine in CD’ (PROFILE) phase IV study is currently 
underway predicting outcomes in CD using a molecular biomarker. This large prospective 
study of 400 patients with CD aims to potentially achieve personalised therapy in CD (105).  
 
Further prospective trials are needed to confirm initial findings and to improve future 
management. 
Table 1 summaries the key treatment targets in CD. 
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Conclusion 
 
Potential treat to target management strategies have been cumulated by international expert 
consensus and are evolving over time. Both endoscopic and clinical remission are recognised 
and obtainable targets for CD. Multiple disease modification studies have been conducted to 
try to prevent long term complications of CD. Biological therapies have the potential to 
become disease modifying agents but more research is needed. Further studies are needed to 
confirm initial findings related to anti-TNF persistence over longer follow up periods and as 
to whether these features translate across to other biologic agents like vedolizumab and 
ustekinumab. Deep remission is the ultimate treatment target to halt the progression of 
disease and improve quality of life. Also, the development of IBD specific disability indices 
can provide a better understanding of the effect of CD on a patient’s well-being. A 
combination of biomarkers aid disease management and an accurate assessment of disease 
activity with cross sectional imaging can improve treatment adjustment. Mucosal healing and 
the absence of luminal disease activity are the most important treatment targets to date. There 
is currently insufficient data to support the use of histological remission. Going forward, 
disease burden as measured through the Lémann score will become a strong therapeutic 
target as it takes into consideration both the patient’s disease burden and clinical findings. 
Further long-term validation datasets in larger cohorts across a number of treatment 
spectrums are needed. Its use in reassessment over time may allow it be a future predictor of 
disease prognosis and the ultimate primary endpoint in clinical practice.  
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Table 1: Summary of Treatment Targets in Crohn’s Disease 
 
 Treatment Target Key References 
Clinical Resolution of abdominal 
pain and bowel habits 
 
Objective evidence of bowel 
inflammation resolution 
Vermeire et al (2010) (19) 
Endoscopic Objective endoscopic 
evidence demonstrating the 
absence of ulceration 
 
Objective evidence of bowel 
inflammation resolution 
Froslie et al (2007) (29) 
 
Baert et al (2010) (38) 
 
Rutter et al (2004) (43) 
Histologic Histological remission is not 
a target 
Baars et al (2010) (66) 
Imaging Inflammation resolution on 
cross sectional imaging 
when endoscopy is unable to 
evaluate this 
Taylor et al (2018) (63) 
 
Pariente et al (2015) (94) 
Biomarkers CRP and FCP are not 
treatment targets 
 
Adjunctive measures of 
inflammation for monitoring 
Reinisch et al (2012) (83) 
 
Wright et al (2015) (90) 
Patient reported outcomes Resolution of abdominal 
pain and the normalization 
of bowel movements 
 
Individual patients’ goals 
should be assessed 
 
Outcome assessment every 
three months until resolution 
Spiegel et al (2014) (25) 
 
Gower-Rousseau et al 
(2017) (100) 
Composite end-points Clinical/PRO remission 
assessed at 3 monthly 
intervals in active disease 
 
Endoscopic remission 
assessed at 6 to 9 months 
during active disease 
Peyrin-Biroule et al (2015) 
(6) 
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Practice Points 
 Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract 
associated with significant morbidity  
 Patients often require lifelong therapy depending on the severity of disease 
 A significant number of patients are primary non-responders or lose response to anti-
TNF therapy 
Research Agenda 
 Further studies are required to determine whether biological therapies have the  
potential to become disease modifying agents 
 Development of molecular biomarkers to help achieve personalised therapy 
 Further advancement of cross sectional imaging to aid clinical decision making 
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